MediBeacon receives NMPA approval for Transdermal GFR System in China; sales expected by year-end

INNOVATE Corp.

NMPA approved Lumitrace (relmapirazin) injection and MediBeacon TGFR Monitor/Sensor for kidney function assessment in China.
TGFR system will be available for sale in China before end of 2025; commercial partnership with Huadong Medicine (est. 2019).
CKD affects ~11% of China's 1.4B people; TGFR offers point-of-care tGFR without blood draws or estimating equations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.